Comparative Pharmacology
Head-to-head clinical analysis: APTIOM versus VALPROIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APTIOM versus VALPROIC ACID.
APTIOM vs VALPROIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.
Increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).
Initial: 10-15 mg/kg/day orally (divided 2-3 times), increase by 5-10 mg/kg/week; maintenance: 30-60 mg/kg/day. IV infusion: same oral dose, rate ≤20 mg/min.
None Documented
None Documented
Clinical Note
moderateValproic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Valproic acid is combined with Fluticasone propionate."
Clinical Note
moderateValproic acid + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valproic acid."
Clinical Note
moderateValproic acid + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Valproic acid."
Clinical Note
moderateValproic acid + Fluconazole
Terminal elimination half-life ranges from 20 to 48 hours (mean ~32 hours). Steady-state achieved within 5-7 days.
Terminal elimination half-life is 9–16 hours in adults; shorter in children (6–9 hours) and longer in neonates (20–30 hours), elderly, or hepatic impairment (up to 18 hours).
Primarily eliminated by hepatic metabolism, with approximately 95% excreted as metabolites in urine and <2% as unchanged drug. Fecal excretion accounts for about 5%.
Primarily hepatic metabolism (>95%), with less than 3% excreted unchanged in urine. Minor fecal excretion (~5%).
Category C
Category D/X
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Valproic acid."